Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

anges in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.

The third study in the Phase 3 program, a multi-center safety study, for which patient recruitment was completed in December 2008, is an ongoing open-label, single-armed study involving 529 patients in North America. The lead investigator is Joel Kaufman, M.D., Associate Clinical Professor in Urology at University of Colorado School of Medicine in Denver, Colorado and at Urology Research Options in Aurora, Colorado.

First efficacy results are expected during the third quarter of 2009 with an NDA filing targeted in 2010.

About Cetrorelix

Cetrorelix pamoate is an investigational agent that has shown in Phase 2 studies to provide fast and long lasting relief of BPH symptoms and was well tolerated, with a low incidence of sexual side effects. Cetrorelix is part of AEterna Zentaris' luteinizing hormone-releasing hormone (LHRH) antagonist therapeutic approach. This peptide-based active substance was developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovulation stimulation/assisted reproductive technologies) in Europe, the USA and Japan. It was launched on the market through Serono (now Merck Serono) in the U.S., Europe and in several other countries, as well as in Japan through Shionogi.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men - affecting more than 20 million men in the United States - but its etiology is far from being completely understood. Data from ongoing research suggest BPH and lower uri
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Florida (PRWEB) April 23, 2015 ... it intends to conduct a groundbreaking pilot study ... to be reversed in as little as three ... science of metabolic and nutritional medicine—will aggressively target ... cripple and destroy our aging brain. These include ...
(Date:4/23/2015)... 2015 Six startups from Russia ... 4-17 as part of the U.S.-Russia Innovation Corridor ... of biotechnology startups to participate in the program ... and the University of Maryland (UMD) signed a ... respective universities in the biomedical industry in 2013. ...
(Date:4/23/2015)... 23, 2015 Follow us ... a series of genetic tests that determine individual ... Gehrig's disease, Huntington's disease, and Alzheimer's disease. Predictive ... composition and interaction in diseased tissue/cells to understand ... as the response to treatment, such as in ...
(Date:4/23/2015)... , April 23, 2015 ... Equipment   Report Details   We ... a value of $101.3 billion in 2015 and will grow ... growth in the healthcare sectors around the world and increasing ... key growth factors in the global healthcare packaging ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10
... in Second Half 2008, ANNAPOLIS, Md., Aug. ... biodefense company developing medical countermeasures,against biological and chemical ... second quarter and six months ended June 30,2008. ... -- Submitted response to a Request for ...
... More than 35% Compared to the previous Quarter ... Production Reaches 200,000 OmniPods per Month, BEDFORD, Mass., Aug. ... patch pump technology with its OmniPod(R),Insulin Management System, today announced ... 30, 2008., Second quarter 2008 reported revenue increased 131% ...
... Biosciences continues to,expand its offering of IRDye ... IRDye(R) 680 Donkey Anti-Chicken IgG, IRDye 800CW,Donkey ... and IRDye 800CW Goat,Anti-Rat IgG antibodies are ... for multiple applications including,quantitative Westerns, In-Cell Westerns, ...
Cached Biology Technology:PharmAthene Reports Second Quarter 2008 Financial and Operational Results 2PharmAthene Reports Second Quarter 2008 Financial and Operational Results 3PharmAthene Reports Second Quarter 2008 Financial and Operational Results 4PharmAthene Reports Second Quarter 2008 Financial and Operational Results 5PharmAthene Reports Second Quarter 2008 Financial and Operational Results 6PharmAthene Reports Second Quarter 2008 Financial and Operational Results 7PharmAthene Reports Second Quarter 2008 Financial and Operational Results 8Insulet Reports Second Quarter 2008 Results 2Insulet Reports Second Quarter 2008 Results 3Insulet Reports Second Quarter 2008 Results 4Insulet Reports Second Quarter 2008 Results 5Insulet Reports Second Quarter 2008 Results 6Insulet Reports Second Quarter 2008 Results 7Insulet Reports Second Quarter 2008 Results 8
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... unique Mayo Clinic collaboration has revived the healing wisdom ... extract described in a 17th century Dutch herbal text ... from the Atun tree effectively control bacteria that can ... circa 1650. He documented his traditional healing methods in ...
... and Hispanic patients and those who are uninsured are less ... been associated with better outcomes, according to a study in ... improve the quality of surgical care in the United States ... hospitals for certain procedures, since a number of studies have ...
... experiments of their kind, researchers at Rice University and ... have determined that carbon nanotubes injected directly into the ... health effects and circulate for more than one hour ... findings are from the first in vivo animal study ...
Cached Biology News:Mayo Clinic collaboration mining of ancient herbal text leads to potential new anti-bacterial drug 2Minorities, uninsured less likely to receive care at high-volume hospitals 2Pure carbon nanotubes pass first in vivo test 2
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
GOAT ANTI PPP2R5B...
... Molecular Probes Fc OxyBURST Green reagent ... Simons of Boston University to permit measurement ... internalization and the subsequent oxidative burst directly ... assay reagent consists of bovine serum albumin ...
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
Biology Products: